(E)-4-(二乙基氨基)丁-2-烯酰胺 | 206126-17-2

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (E)-4-(二乙基氨基)丁-2-烯酰胺
• 英文名称: (E)-4-(Diethylamino)but-2-enamide
• CAS: 206126-17-2
• 化学式: C₈H₁₆N₂O
• 分子量: 156.228
• InChiKey: SFPGNABUJLHMNQ-AATRIKPKSA-N

物化性质

• 沸点：
  295.3±32.0 °C(Predicted)
• 密度：
  0.962±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-4-(二乙基氨基)丁-2-烯酰胺 在 甲酸 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Synthesis and Biological Activity of Quaternary Ammoniopropenyl Cephalosporins having Two Vinyl Groups.

  摘要：

  DOI：

  10.7164/antibiotics.51.378
• 作为产物：
  描述：

  4-溴丁-2-烯腈 、 二乙胺 以 乙腈 为溶剂， 反应 1.0h， 生成 (E)-4-(二乙基氨基)丁-2-烯酰胺
  参考文献：
  名称：

  Synthesis and Biological Activity of Quaternary Ammoniopropenyl Cephalosporins having Two Vinyl Groups.

  摘要：

  DOI：

  10.7164/antibiotics.51.378

文献信息

• CYANOQUINOLINE DERIVATIVES
  申请人：Zhang Hesheng

  公开号：US20130225579A1

  公开（公告）日：2013-08-29

  Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R 1 , R 2 , R 3 and R 4 are each as defined in the present application.

  公开了一种公式I的化合物，其立体异构体，其顺反异构体，其互变异构体，或它们的混合物，或其药物可接受的盐，其溶剂化物或其前药，其中R1，R2，R3和R4各自如在本申请中定义。
• Quinazoline derivatives
  申请人：Kitano Yasunori

  公开号：US20070265260A1

  公开（公告）日：2007-11-15

  A compound of the formula (I) or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.

  化合物(I)的配方或其药学上可接受的盐、水合物、溶剂合物、其光学活性化合物、其外消旋体混合物或其差向异构体混合物具有优越的酪氨酸特异性蛋白激酶抑制活性，并可用作药物制剂，特别是用作预防或治疗各种癌症、银屑病或动脉硬化引起的疾病等的药物。
• Cyanoquinoline derivatives
  申请人：Tianjin Hemay Oncoloy Pharmaceutical Co., Ltd.

  公开号：US10246443B2

  公开（公告）日：2019-04-02

  Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.

  公开了一种式 I 的化合物、其立体异构体、顺反异构体、同系物或其混合物，或其药学上可接受的盐、溶液或原药、 其中 R1、R2、R3 和 R4 各如本申请中所定义。
• Substituted heterocyclyl derivatives as CDK inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US11174232B2

  公开（公告）日：2021-11-16

  The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

  本发明提供了式(I)的取代杂环二烯丙基衍生物，它们具有治疗作用，特别是作为选择性转录CDK抑制剂，包括CDK7、CDK9、CDK12、CDK13和CDK18，更特别是转录CDK7抑制剂。这些化合物可用于治疗和预防哺乳动物中与选择性转录 CDK 相关的疾病和/或失调。本发明还提供了包含至少一种式（I）的取代杂环烷基衍生物或其药学上可接受的盐或立体异构体的化合物和药物制剂的制备方法。
• Substituted Heterocyclyl Derivatives as CDK Inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US20200262793A1

  公开（公告）日：2020-08-20

  The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.